The FDA has unveiled a comprehensive suite of draft guidance aimed at enhancing the credibility of artificial intelligence (AI) models used in drug and biological product submissions. This new framework highlights the risks associated with AI technology, particularly in drug development processes. Key recommendations include the use of tissue biopsies in clinical trials only when necessary and low risk, and a focus on lifecycle management for AI-enabled medical devices. Companies are encouraged to think beyond initial approvals as they navigate the evolving landscape of AI integration into medical device manufacturing. The guidance provides critical insights for developers, marking a significant shift in regulatory practices and potentially influencing the market, as seen by the surge of GeneDx, a notable stock in this area.